XOMA Royalty (XOMA) Research & Development (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Research & Development came in at $49000.0 in Q1 2026, down 96.21% year-on-year from $1.3 million in Q1 2025, and down 82.56% quarter-over-quarter from $281000.0 in Q4 2025.
XOMA Royalty (XOMA) Research & Development (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Research & Development across 16 years of filings, most recently posting $49000.0 for Q1 2026.
- Research & Development for Q1 2026 came in at $49000.0, down 96.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $468000.0 (down 88.68% YoY), and the FY2025 annual result was $1.7 million, down 40.45% from the prior year.
- Research & Development came in at $49000.0 for Q1 2026 at XOMA Royalty, down from $281000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.3 million in Q1 2025 to a low of $25000.0 in Q3 2023.
- The 5-year median for Research & Development is $54000.0 (2023), against an average of $290117.6.
- Across the five-year window, Research & Development soared 3818.18% in 2025 and sank 96.21% in 2026, its largest moves.
- XOMA Royalty's Research & Development stood at $28000.0 in 2022, then slipped by 10.71% to $25000.0 in 2023, then jumped by 3356.0% to $864000.0 in 2024, then plunged by 67.48% to $281000.0 in 2025, then plunged by 82.56% to $49000.0 in 2026.
- The last three Research & Development figures came in at $49000.0 (Q1 2026), $281000.0 (Q4 2025), and $69000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -58.00 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 281,000.00 |
| Sep 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 864,000.00 |
| Sep 30, 2024 | 817,000.00 |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 39,000.00 |
| Mar 31, 2023 | 54,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Mar 31, 2022 | 56,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 38,000.00 |